Kazia Therapeutics Limite... (KZIA)
Kazia Therapeutics Statistics
Share Statistics
Kazia Therapeutics has 3.33M shares outstanding. The number of shares has increased by 40.83% in one year.
| Shares Outstanding | 3.33M |
| Shares Change (YoY) | 40.83% |
| Shares Change (QoQ) | 11.81% |
| Owned by Institutions (%) | 0.89% |
| Shares Floating | 2.91M |
| Failed to Deliver (FTD) Shares | 130.44K |
| FTD / Avg. Volume | 6.81% |
Short Selling Information
The latest short interest is 18.77K, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 18.77K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.06% |
| Short Ratio (days to cover) | 0.11 |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is null. Kazia Therapeutics's PEG ratio is -0.05.
| PE Ratio | -0.03 |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | 0.1 |
| PB Ratio | -0.08 |
| P/FCF Ratio | -0.08 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kazia Therapeutics Limited.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24, with a Debt / Equity ratio of -0.06.
| Current Ratio | 0.24 |
| Quick Ratio | 0.24 |
| Debt / Equity | -0.06 |
| Total Debt / Capitalization | -6.76 |
| Cash Flow / Debt | -15.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 2.67% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | 2.67% |
| Return on Assets (ROA) | -1.24% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $256,444.44 |
| Profits Per Employee | $-2,975,333.33 |
| Employee Count | 9 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -271K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -66.93% in the last 52 weeks. The beta is 2.11, so Kazia Therapeutics's price volatility has been higher than the market average.
| Beta | 2.11 |
| 52-Week Price Change | -66.93% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 30.61 |
| Average Volume (20 Days) | 1.92M |
Income Statement
In the last 12 months, Kazia Therapeutics had revenue of 2.31M and earned -26.78M in profits. Earnings per share was -11.17.
| Revenue | 2.31M |
| Gross Profit | 2.31M |
| Operating Income | 0 |
| Net Income | -26.78M |
| EBITDA | -26.77M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -11.17 |
Balance Sheet
The company has 1.66M in cash and 634K in debt, giving a net cash position of 1.02M.
| Cash & Cash Equivalents | 1.66M |
| Total Debt | 634K |
| Net Cash | 1.02M |
| Retained Earnings | -115.13M |
| Total Assets | 21.59M |
| Working Capital | -19.65M |
Cash Flow
In the last 12 months, operating cash flow was -9.58M and capital expenditures 0, giving a free cash flow of -9.58M.
| Operating Cash Flow | -9.58M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.58M |
| FCF Per Share | -4 |
Margins
Gross margin is 100%, with operating and profit margins of 0% and -1.16K%.
| Gross Margin | 100% |
| Operating Margin | n/a |
| Pretax Margin | -1.17K% |
| Profit Margin | -1.16K% |
| EBITDA Margin | -1.16K% |
| EBIT Margin | n/a |
| FCF Margin | -415.12% |
Dividends & Yields
KZIA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1314.12% |
| FCF Yield | -338.09% |
Analyst Forecast
The average price target for KZIA is $11.5, which is 1252.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 1252.9% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 28, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 28, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -15.52 |
| Piotroski F-Score | 1 |